第一三共(株)【4568】の掲示板 2015/09/23〜2015/12/25

Roche receives EU approval of Cotellic for use in combination with Zelboraf (PLX4032; Plexxikon) in advanced melanoma
Basel, 25 November 2015

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved CotellicTM (cobimetinib) for use in combination with Zelboraf® (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EU approval is based on data that showed Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live for more than a year without their disease worsening.

http://www.roche.com/media/store/releases/med-cor-2015-11-25.htm